Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Prog Urol ; 28(8-9): 450-459, 2018 Jun.
Artigo em Francês | MEDLINE | ID: mdl-29789236

RESUMO

INTRODUCTION: This study aims to assess the effectiveness of triptorelin on lower urinary tract symptoms (LUTS) in Algerian patients with non-localized prostate cancer in routine practice. MATERIALS: This prospective, observational, non-interventional, multicentre study was conducted in Algeria. Included patients who had locally advanced or metastatic prostate cancer and were treated with triptorelin 11.25mg given every 12 weeks. LUTS were evaluated with the International Prostate Symptom Score (IPSS) until week 48 after treatment initiation. An IPSS>7 indicated moderate to severe LUTS. The primary objective of the study was to determine the distribution of IPSS at week 48. RESULTS: This study enrolled 193 patients at 21 centres. A total of 144 participants had IPSS available at baseline and after baseline (136 patients had moderate to severe LUTS and eight had mild LUTS at baseline). At week 48, amongst the 116 patients with IPSS available and moderate to severe LUTS at baseline, 94 (81.0%) had moderate to severe LUTS and 22 (19.0%) had mild LUTS. At week 48, the eight patients with mild symptoms at baseline remained in this category. The proportion of patient with severe LUTS decreased from 53.7% at baseline to 12.1% at week 48. Adverse events were reported in 22.9% of participants. CONCLUSION: A reduction of LUTS is observed in patients with locally advanced or metastatic prostate cancer treated with triptorelin in routine practice. This is in agreement with similar observational studies of triptorelin conducted in other countries. LEVEL OF PROOF: 4.


Assuntos
Sintomas do Trato Urinário Inferior/tratamento farmacológico , Neoplasias da Próstata/tratamento farmacológico , Neoplasias da Próstata/patologia , Pamoato de Triptorrelina/uso terapêutico , Idoso , Idoso de 80 Anos ou mais , Argélia , Progressão da Doença , Humanos , Injeções Intramusculares , Sintomas do Trato Urinário Inferior/etiologia , Masculino , Pessoa de Meia-Idade , Metástase Neoplásica , Atenção Primária à Saúde/estatística & dados numéricos , Neoplasias da Próstata/complicações , Resultado do Tratamento , Pamoato de Triptorrelina/administração & dosagem
2.
Br J Cancer ; 101(7): 1207-12, 2009 Oct 06.
Artigo em Inglês | MEDLINE | ID: mdl-19724280

RESUMO

BACKGROUND: The lifestyle risk factors for nasopharyngeal carcinoma (NPC) in North Africa are not known. METHODS: From 2002 to 2005, we interviewed 636 patients and 615 controls from Algeria, Morocco and Tunisia, frequency-matched by centre, age, sex, and childhood household type (urban/rural). Conditional logistic regression was used to evaluate the association of lifestyles with NPC risk, controlling for socioeconomic status and dietary risk factors. RESULTS: Cigarette smoking and snuff (tobacco powder with additives) intake were significantly associated with differentiated NPC but not with undifferentiated carcinoma (UCNT), which is the major histological type of NPC in these populations. As demonstrated by a stratified permutation test and by conditional logistic regression, marijuana smoking significantly elevated NPC risk independently of cigarette smoking, suggesting dissimilar carcinogenic mechanisms between cannabis and tobacco. Domestic cooking fumes intake by using kanoun (compact charcoal oven) during childhood increased NPC risk, whereas exposure during adulthood had less effect. Neither alcohol nor shisha (water pipe) was associated with risk. CONCLUSION: Tobacco, cannabis and domestic cooking fumes intake are risk factors for NPC in western North Africa.


Assuntos
Poluição do Ar em Ambientes Fechados/efeitos adversos , Culinária , Fumar Maconha/efeitos adversos , Neoplasias Nasofaríngeas/etiologia , Fumar/efeitos adversos , Estudos de Casos e Controles , Feminino , Humanos , Masculino , Análise Multivariada , Fatores de Risco , Fumaça , Tabaco sem Fumaça/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA